NCT01944787

Brief Summary

The hypothesis of the present study is the hydration of nulliparous women with 250ml/hour vs. 125ml/hrs would decrease the rate of primary cesarean section.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
670

participants targeted

Target at P75+ for not_applicable pregnancy

Timeline
Completed

Started Sep 2013

Longer than P75 for not_applicable pregnancy

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2013

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

September 6, 2013

Completed
12 days until next milestone

First Posted

Study publicly available on registry

September 18, 2013

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2018

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2018

Completed
Last Updated

September 18, 2013

Status Verified

September 1, 2013

Enrollment Period

4.3 years

First QC Date

September 6, 2013

Last Update Submit

September 17, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • rate of cesarean section

    The primary objective of this multi-center RCT is to determine if hydration with 250 ml/hr, when compared to traditional 125 ml/hr, significantly decreases the rate of primary cesarean delivery nulliparous.

    5 Years

Secondary Outcomes (1)

  • labor

    5 Years

Other Outcomes (8)

  • The rate of tachysystole (uterine contractions more than 5 in 10 minutes, n/%)

    5 Years

  • The rate of non-reassuring fetal-heart reassuring tracing treated with terbutaline or other tocolytic agent (n/%)

    5 Years

  • The indication for cesarean delivery (n/%) versus The indication for operative vaginal delivery (n/%)

    5 Years

  • +5 more other outcomes

Study Arms (2)

Routine

ACTIVE COMPARATOR

IV Hydration at 125 cc hour

Other: Routine

Intervention

EXPERIMENTAL

IV Hydration at 250 cc hour

Other: IV Hydration at 250cc hour

Interventions

RoutineOTHER

IV Hydration at 125 cc hour

Routine

IV Hydration at 250 cc hour

Intervention

Eligibility Criteria

Age18 Years - 55 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Nulliparous (no prior delivery after 20 weeks)
  • Presenting at ≥37 weeks of gestation
  • Presenting for anticipated induction of labor or spontaneous labor (regular contractions for more than 2 hours), but cervical dilation less than 4 cm
  • Rupture of membranes
  • Expected to deliver at one of the participating hospitals

You may not qualify if:

  • Autoimmune disorders (antiphospholipid antibody, lupus, rheumatoid arthritis, scleroderma)
  • Diabetes mellitus-gestational or pre-gestational
  • Enrollment in another randomized clinical trial
  • Hematologic disorders (coagulation defects, sickle cell disease, thrombocytopenia, thrombophilia)
  • Hypertension (chronic or pregnancy induced) before randomization
  • HIV (human immunodeficiency virus)
  • Placenta previa / 3rd trimester bleeding
  • Renal insufficiency (serum creatinine \> 1.5 mg/dL)
  • Restrictive lung disease
  • Seizure disorder on medication
  • Thyroid disease on medication
  • Any contraindications to vaginal delivery (breech, active herpes, schedule cesarean, abnormal fetal heart tracing)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

C A Combs MD PhD

Campbell, California, 95008, United States

Location

Study Officials

  • Suneet P Chauhan, MD

    PRINCIPAL INVESTIGATOR
  • Andrew Combs, MD PhD

    Obstetrix Medical Group

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Suneet Chauhan, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
INDIV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 6, 2013

First Posted

September 18, 2013

Study Start

September 1, 2013

Primary Completion

January 1, 2018

Study Completion

July 1, 2018

Last Updated

September 18, 2013

Record last verified: 2013-09

Locations